Viridian Therapeutics, Inc. $VRDN Shares Purchased by Knott David M Jr

Knott David M Jr boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 24.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 181,000 shares of the company’s stock after purchasing an additional 36,000 shares during the quarter. Viridian Therapeutics makes up approximately 2.1% of Knott David M Jr’s holdings, making the stock its 14th largest holding. Knott David M Jr’s holdings in Viridian Therapeutics were worth $3,540,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Sei Investments Co. boosted its stake in shares of Viridian Therapeutics by 117.0% during the 1st quarter. Sei Investments Co. now owns 65,777 shares of the company’s stock valued at $1,287,000 after buying an additional 35,459 shares during the last quarter. State of Wyoming bought a new stake in shares of Viridian Therapeutics in the first quarter worth $93,000. First Trust Advisors LP increased its stake in shares of Viridian Therapeutics by 151.5% in the first quarter. First Trust Advisors LP now owns 301,529 shares of the company’s stock worth $5,898,000 after buying an additional 181,637 shares during the last quarter. KBC Group NV acquired a new stake in Viridian Therapeutics in the first quarter valued at $34,000. Finally, SEB Asset Management AB acquired a new stake in Viridian Therapeutics in the first quarter valued at $3,070,000.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $19.26 on Friday. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -5.80 and a beta of 0.90. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29. The business has a 50 day simple moving average of $17.65 and a 200-day simple moving average of $22.48.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.16. The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The firm’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same period last year, the business posted ($0.87) earnings per share. As a group, equities research analysts expect that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the company’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the acquisition, the director owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, May 13th. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a research note on Friday, May 15th. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Monday, June 29th. Finally, Wells Fargo & Company upgraded Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.79.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.